p.101 抽出テキスト

the follow-up of patients with idiopathic pulmonary arterial hypertension. Chest 2021;159:1575–1585. 238. Weatherald J, Boucly A, Chemla D, Savale L, Peng M, Jevnikar M, et al. Prognostic value of follow-up hemodynamic variables after initial management in pulmonary arterial hypertension. Circulation 2018;137:693–704. 239. van Wolferen SA, van de Veerdonk MC, Mauritz GJ, Jacobs W, Marcus JT, Marques KMJ, et al. Clinically significant change in stroke volume in pulmonary hypertension. Chest 2011;139:1003–1009. 240. Huis In ‘t Veld AE, Van de Veerdonk MC, Spruijt O, Groeneveldt JA, Marcus JT, Westerhof N, et al. EXPRESS: preserving right ventricular function in patients with pulmonary arterial hypertension: single centre experience with a cardiac magnetic resonance imaging-guided treatment strategy. Pulm Circ 2019. doi:10.1177/2045894018824553. Epub ahead of print. 241. van de Veerdonk MC, Huis In T Veld AE, Marcus JT, Westerhof N, Heymans MW, Bogaard HJ, et al. Upfront combination therapy reduces right ventricular volumes in pulmonary arterial hypertension. Eur Respir J 2017;49:1700007. 242. van de Veerdonk MC, Marcus JT, Westerhof N, de Man FS, Boonstra A, Heymans MW, et al. Signs of right ventricular deterioration in clinically stable patients with pulmonary arterial hypertension. Chest 2015;147:1063–1071. 243. D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343–349. 244. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156–163. 245. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477–1482. 246. Provencher S, Chemla D, Herve P, Sitbon O, Humbert M, Simonneau G. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. Eur Respir J 2006;27:114–120. 247. Sitbon O, Benza RL, Badesch DB, Barst RJ, Elliott CG, Gressin V, et al. Validation of two predictive models for survival in pulmonary arterial hypertension. Eur Respir J 2015;46:152–164. 248. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010;35:1079–1087. 249. Benza RL, Gomberg-Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest 2019;156:323–337. 250. Benza RL, Gomberg-Maitland M, Miller DP, Frost A, Frantz RP, Foreman AJ, et al. The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest 2012;141:354–362. 251. Savarese G, Paolillo S, Costanzo P, D’Amore C, Cecere M, Losco T, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012;60:1192–1201. 252. Zelniker TA, Huscher D, Vonk-Noordegraaf A, Ewert R, Lange TJ, Klose H, et al. The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry. Clin Res Cardiol 2018;107:460–470. 253. Farber HW, Miller DP, McGoon MD, Frost AE, Benton WW, Benza RL. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. J Heart Lung Transpl 2015;34:362–368. 254. Heresi GA, Rao Y. Follow-up functional class and 6-minute walk distance identify long-term survival in pulmonary arterial hypertension. Lung 2020;198:933–938. 255. Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, et al. Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: data from the randomized SERAPHIN trial. PLoS One 2018;13:e0193226. 256. Halliday SJ, Wang L, Yu C, Vickers BP, Newman JH, Fremont RD, et al. Six-minute walk distance in healthy young adults. Respir Med 2020;165:105933. 257. Khirfan G, Naal T, Abuhalimeh B, Newman J, Heresi GA, Dweik RA, et al. Hypoxemia in patients with idiopathic or heritable pulmonary arterial hypertension. PLoS One 2018;13:e0191869. 258. Lewis RA, Billings CG, Hurdman JA, Smith IA, Austin M, Armstrong IJ, et al. Maximal exercise testing using the incremental shuttle walking test can be used to riskstratify patients with pulmonary arterial hypertension. Ann Am Thorac Soc 2021; 18:34–43. 259. Laveneziana P, Di Paolo M, Palange P. The clinical value of cardiopulmonary exercise testing in the modern era. Eur Respir Rev 2021;30:200187. 260. Wensel R, Opitz CF, Anker SD, Winkler J, Hoffken G, Kleber FX, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002;106:319–324. 261. Badagliacca R, Papa S, Poscia R, Valli G, Pezzuto B, Manzi G, et al. The added value of cardiopulmonary exercise testing in the follow-up of pulmonary arterial hypertension. J Heart Lung Transpl 2019;38:306–314. 262. Deboeck G, Scoditti C, Huez S, Vachiery JL, Lamotte M, Sharples L, et al. Exercise testing to predict outcome in idiopathic versus associated pulmonary arterial hypertension. Eur Respir J 2012;40:1410–1419. 263. Wensel R, Francis DP, Meyer FJ, Opitz CF, Bruch L, Halank M, et al. Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension. Int J Cardiol 2013;167:1193–1198. 264. Badagliacca R, Rischard F, Giudice FL, Howard L, Papa S, Valli G, et al. Incremental value of cardiopulmonary exercise testing in intermediate-risk pulmonary arterial hypertension. J Heart Lung Transplant 2022;41:780–790. 265. Bouzina H, Rådegran G. Low plasma stem cell factor combined with high transforming growth factor-α identifies high-risk patients in pulmonary arterial hypertension. ERJ Open Res 2018;4:00035-02018. 266. Chin KM, Rubin LJ, Channick R, Di Scala L, Gaine S, Galiè N, et al. Association of N-terminal pro brain natriuretic peptide and long-term outcome in patients with pulmonary arterial hypertension: insights from the phase III GRIPHON study. Circulation 2019;139:2440–2450. 267. Frantz RP, Farber HW, Badesch DB, Elliott CG, Frost AE, McGoon MD, et al. Baseline and serial brain natriuretic peptide level predicts 5-year overall survival in patients with pulmonary arterial hypertension: data from the REVEAL registry. Chest 2018;154:126–135. 268. Harbaum L, Ghataorhe P, Wharton J, Jimenez B, Howard LSG, Gibbs JSR, et al. Reduced plasma levels of small HDL particles transporting fibrinolytic proteins in pulmonary arterial hypertension. Thorax 2019;74:380–389. 269. Naal T, Abuhalimeh B, Khirfan G, Dweik RA, Tang WHW, Tonelli AR. Serum chloride levels track with survival in patients with pulmonary arterial hypertension. Chest 2018;154:541–549. 270. Nikolic I, Yung LM, Yang P, Malhotra R, Paskin-Flerlage S, Dinter T, et al. Bone morphogenetic protein 9 is a mechanistic biomarker of portopulmonary hypertension. Am J Respir Crit Care Med 2019;199:891–902. 271. Rhodes CJ, Wharton J, Ghataorhe P, Watson G, Girerd B, Howard LS, et al. Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. Lancet Respir Med 2017;5:717–726. 272. Wetzl V, Tiede SL, Faerber L, Weissmann N, Schermuly RT, Ghofrani HA, et al. Plasma MMP2/TIMP4 ratio at follow-up assessment predicts disease progression of idiopathic pulmonary arterial hypertension. Lung 2017;195:489–496. 273. Arvidsson M, Ahmed A, Bouzina H, Rådegran G. Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension. Pulm Circ 2019;9: 2045894019895414. 274. Kylhammar D, Hesselstrand R, Nielsen S, Scheele C, Radegran G. Angiogenic and inflammatory biomarkers for screening and follow-up in patients with pulmonary arterial hypertension. Scand J Rheumatol 2018;47:319–324. 275. Saleby J, Bouzina H, Ahmed S, Lundgren J, Radegran G. Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation. ERJ Open Res 2019;5:00037–02019. 276. van Bon L, Affandi AJ, Broen J, Christmann RB, Marijnissen RJ, Stawski L, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 2014;370:433–443. 277. Ferrer E, Dunmore BJ, Hassan D, Ormiston ML, Moore S, Deighton J, et al. A potential role for exosomal translationally controlled tumor protein export in vascular remodeling in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2018;59: 467–478. 278. Lavoie JR, Ormiston ML, Perez-Iratxeta C, Courtman DW, Jiang B, Ferrer E, et al. Proteomic analysis implicates translationally controlled tumor protein as a novel mediator of occlusive vascular remodeling in pulmonary arterial hypertension. Circulation 2014;129:2125–2135. 279. Warwick G, Thomas PS, Yates DH. Biomarkers in pulmonary hypertension. Eur Respir J 2008;32:503–512. 280. Hoeper M, Pausch C, Olsson K, Huscher D, Pittrow D, Grünig E, et al. COMPERA 2.0: a refined 4-strata risk assessment model for pulmonary arterial hypertension. Eur Respir J 2022;60:2102311. 281. Delcroix M, Howard L. Pulmonary arterial hypertension: the burden of disease and impact on quality of life. Eur Respir Rev 2015;24:621–629. 282. Yorke J, Corris P, Gaine S, Gibbs JS, Kiely DG, Harries C, et al. emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. Eur Respir J 2014;43:1106–1113. 283. McGoon MD, Ferrari P, Armstrong I, Denis M, Howard LS, Lowe G, et al. The importance of patient perspectives in pulmonary hypertension. Eur Respir J 2019;53: 1801919. 284. Twiss J, McKenna S, Ganderton L, Jenkins S, Ben-L’amri M, Gain K, et al. Psychometric performance of the CAMPHOR and SF-36 in pulmonary hypertension. BMC Pulm Med 2013;13:45. Downloaded from academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 07 October 2026